Zeiss Clarus 700 Receives NMPA Approval in China

Zeiss Medical Technology announced that the Clarus 700 has received National Medical Products Administration (NMPA) approval in China.

According to Zeiss, the Clarus 700 offers advanced retinal diagnostic capabilities with ultra-widefield, high-resolution images in true color. The fundus imaging device with fluorescein angiography is designed to help eye care specialists in China unlock the full potential of their clinic’s retina workflow to support improved patient vision preservation.

"Zeiss Clarus 700 represents a major step forward in retinal imaging," Anuj Kalra, Head of Chronic Disease Management at Zeiss Medical Technology, said in a company news release. "By seamlessly integrating ultra-widefield fluorescein angiography (FA) imaging with true-color reproduction, this system delivers unprecedented clarity for comprehensive visualization from the macular region to the extreme retinal periphery, enhancing efficiency and supporting precise decision-making within the Zeiss Retina Workflow."

The Zeiss Clarus 700 HD captures 133°[1] in a single image and up to 267° with multiple captures, offering detailed views of the retina. Equipped with both fluorescein angiography and live infrared imaging capabilities, the Clarus 700 aids in diagnosing and monitoring retinal diseases.[2] Furthermore, the fundus imaging camera includes technology features including 'PrecisionFocus' for quickly seeing details in the regions of interest, 'QuickCompare' to compare pathology changes observed in past patient visits, and 'AutoBright' so ophthalmologists can spend more time analyzing images and less time adjusting them.

More information about the Clarus 700 can be found here.